151 related articles for article (PubMed ID: 30824607)
1. Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.
Li F; Ulrich ML; Shih VF; Cochran JH; Hunter JH; Westendorf L; Neale J; Benjamin DR
Mol Cancer Ther; 2019 Apr; 18(4):780-787. PubMed ID: 30824607
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.
Li F; Ulrich M; Jonas M; Stone IJ; Linares G; Zhang X; Westendorf L; Benjamin DR; Law CL
Mol Cancer Ther; 2017 Jul; 16(7):1347-1354. PubMed ID: 28341790
[TBL] [Abstract][Full Text] [Related]
3. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
Oldham RJ; Mockridge CI; James S; Duriez PJ; Chan HTC; Cox KL; Pitic VA; Glennie MJ; Cragg MS
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554613
[TBL] [Abstract][Full Text] [Related]
4. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
5. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
6. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
7. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
9. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
[TBL] [Abstract][Full Text] [Related]
10. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
[TBL] [Abstract][Full Text] [Related]
11. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
13. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
14. Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension.
Li Q; Barrett A; Vijayakrishnan B; Tiberghien A; Beard R; Rickert KW; Allen KL; Christie RJ; Marelli M; Harper J; Howard P; Wu H; Dall'Acqua WF; Tsui P; Gao C; Borrok MJ
Bioconjug Chem; 2019 Apr; 30(4):1232-1243. PubMed ID: 30912649
[TBL] [Abstract][Full Text] [Related]
15. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
[TBL] [Abstract][Full Text] [Related]
17. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
18. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.
Staudacher AH; Liapis V; Wittwer NL; Tieu W; Lam HC; Leusen J; Brown MP
Biomed Pharmacother; 2022 Jul; 151():113090. PubMed ID: 35567988
[TBL] [Abstract][Full Text] [Related]
19. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
[TBL] [Abstract][Full Text] [Related]
20. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
